JUNSHI BIO (01877) shares climbed more than 3% in Hong Kong trading, last up 3.07% at HK$17.11 with turnover reaching HK$19.955 million. The rally comes as investors reacted positively to the company's latest pipeline updates.

During the 2026 interim results briefing held on September 14, the company disclosed the most recent development progress of its core innovative drug pipeline. Management confirmed that both highly anticipated bispecific antibody candidates are scheduled to initiate pivotal Phase III clinical studies within 2026.

Among the two programs, JS203, a CD20/CD3-targeting bispecific antibody, is set to officially advance into the Phase III clinical stage. Meanwhile, JS207, which targets PD-1/VEGF, is currently in Phase II studies, with active exploration of combination therapies involving chemotherapy, monoclonal antibodies, and ADCs across multiple tumor types. This second candidate is also expected to commence Phase III trials within the same timeframe.